Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
116-hr-7296116th Congress
MMAPPP Act of 2020
Sponsored By: Representative Schakowsky, Janice D. [D-IL-9]
Unknown
Summary
Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020 This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies. With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill. The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access. If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
No Economic Impacts Identified for this Bill
Sponsors & CoSponsors
Sponsor
Schakowsky, Janice D. [D-IL-9]
IL • D
Cosponsors
Sen. Welch, Peter [D-VT]
VT • D
Sponsored 7/6/2020
Rep. McCollum, Betty [D-MN-4]
MN • D
Sponsored 7/6/2020
Rep. Pingree, Chellie [D-ME-1]
ME • D
Sponsored 7/6/2020
Rep. Carson, André [D-IN-7]
IN • D
Sponsored 7/6/2020
Rep. Cohen, Steve [D-TN-9]
TN • D
Sponsored 7/6/2020
Rep. Huffman, Jared [D-CA-2]
CA • D
Sponsored 7/6/2020
Del. San Nicolas, Michael F. Q. [D-GU-At Large]
GU • D
Sponsored 7/20/2020
Rep. Napolitano, Grace F. [D-CA-31]
CA • D
Sponsored 7/20/2020
Rep. Luria, Elaine G. [D-VA-2]
VA • D
Sponsored 8/7/2020
Rep. Hastings, Alcee L. [D-FL-20]
FL • D
Sponsored 8/7/2020
Rep. Gabbard, Tulsi [D-HI-2]
HI • D
Sponsored 8/7/2020
Rep. DeSaulnier, Mark [D-CA-10]
CA • D
Sponsored 8/18/2020
Rep. Lawson, Al, Jr. [D-FL-5]
FL • D
Sponsored 8/18/2020
Rep. Rose, Max [D-NY-11]
NY • D
Sponsored 9/25/2020
Rep. Grijalva, Raúl M. [D-AZ-7]
AZ • D
Sponsored 9/25/2020
Rep. Evans, Dwight [D-PA-3]
PA • D
Sponsored 10/23/2020
Rep. Price, David E. [D-NC-4]
NC • D
Sponsored 10/30/2020
Rep. Titus, Dina [D-NV-1]
NV • D
Sponsored 10/30/2020
Rep. Rooney, Francis [R-FL-19]
FL • R
Sponsored 6/22/2020
Rep. Doggett, Lloyd [D-TX-37]
TX • D
Sponsored 6/22/2020
Rep. DeLauro, Rosa L. [D-CT-3]
CT • D
Sponsored 6/22/2020
Rep. DeFazio, Peter A. [D-OR-4]
OR • D
Sponsored 6/22/2020
Rep. Pocan, Mark [D-WI-2]
WI • D
Sponsored 6/22/2020
Rep. Jayapal, Pramila [D-WA-7]
WA • D
Sponsored 6/22/2020
Rep. Velázquez, Nydia M. [D-NY-7]
NY • D
Sponsored 6/24/2020
Rep. Bishop, Sanford D. [D-GA-2]
GA • D
Sponsored 6/26/2020
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 7/6/2020
Rep. Hayes, Jahana [D-CT-5]
CT • D
Sponsored 7/6/2020
Rep. Raskin, Jamie [D-MD-8]
MD • D
Sponsored 7/6/2020
Rep. Porter, Katie [D-CA-47]
CA • D
Sponsored 7/6/2020
Rep. Scanlon, Mary Gay [D-PA-5]
PA • D
Sponsored 7/6/2020
Rep. Khanna, Ro [D-CA-17]
CA • D
Sponsored 7/20/2020
Rep. Chu, Judy [D-CA-28]
CA • D
Sponsored 8/7/2020
Rep. Phillips, Dean [D-MN-3]
MN • D
Sponsored 12/2/2020
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov